Overcoming Drug-resistant Herpes Simplex Virus (HSV) Infection by a Humanized Antibody

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2013 Apr 10

PMID 23569258

Citations 44

Authors

Adalbert Krawczyk

Michaela A E Arndt

Ludger Grosse-Hovest

Wilko Weichert

Bernd Giebel

Ulf Dittmer

Hartmut Hengel

Dirk Jager

Karl E Schneweis

Anna M Eis-Hubinger

Michael Roggendorf

Jurgen Krauss

Affiliations

Soon will be listed here.

Abstract

Despite the availability of antiviral chemotherapy, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain a severe global health problem. Of particular concern is the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency to develop new effective treatment alternatives. We have developed a humanized monoclonal antibody (mAb hu2c) that completely abrogates viral cell-to-cell spread, a key mechanism by which HSV-1/2 escapes humoral immune surveillance. Moreover, mAb hu2c neutralized HSV fully independent of complement and/or immune effector cell recruitment in a highly efficient manner. Prophylactic and therapeutic administration of mAb hu2c completely prevented infection-related mortality of severely immunodeficient mice being challenged with a lethal dose of HSV-1. The high neutralization capacity of mAb hu2c was fully maintained toward clinical HSV isolates being multiresistant to standard antiviral drugs, and infection was fully resolved in 7/8 nonobese diabetic/SCID mice being infected with a multidrug resistant HSV-1 patient isolate. Immunohistochemical studies revealed no significant cross-reactivity of the antibody toward human tissues. These features warrant further clinical development of mAb hu2c as an immunotherapeutic compound for the management of severe and particularly drug-resistant HSV infections.

Citing Articles

Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy.

El-Qassas J, Abd El-Atti M, El-Badri N Bioresour Bioprocess. 2024; 11(1):93.

PMID: 39361208 PMC: 11450130. DOI: 10.1186/s40643-024-00805-0.

Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus.

Seyfizadeh N, Kalbermatter D, Imhof T, Ries M, Muller C, Jenner L J Biomed Sci. 2024; 31(1):56.

PMID: 38807208 PMC: 11134845. DOI: 10.1186/s12929-024-01045-2.

Ligand-based drug design against Herpes Simplex Virus-1 capsid protein by modification of limonene through in silico approaches.

Islam M, Islam Sovon M, Amena U, Rahman M, Hosen M, Kumer A Sci Rep. 2024; 14(1):9828.

PMID: 38684729 PMC: 11058824. DOI: 10.1038/s41598-024-59577-4.

Therapeutic Potential of Biochanin A in Herpes Simplex Keratitis.

Zhou N, Zheng D, You Q, Chen T, Jiang J, Shen W Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765049 PMC: 10536220. DOI: 10.3390/ph16091240.

Effects of Melatonin Alone or Associated with Acyclovir on the Suppressive Treatment of Recurrent Genital Herpes: A Prospective, Randomized, and Double-Blind Study.

Roa C, Cipolla-Neto J, Reiter R, Linhares I, Lepique A, de Aguiar L Biomedicines. 2023; 11(4).

PMID: 37189706 PMC: 10135732. DOI: 10.3390/biomedicines11041088.

References

Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M . Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer. 2009; 45(18):3131-48. DOI: 10.1016/j.ejca.2009.08.010. View

Co M, Avdalovic N, Caron P, Avdalovic M, Scheinberg D, Queen C . Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol. 1992; 148(4):1149-54. View

Baeten J, Strick L, Lucchetti A, Whittington W, Sanchez J, Coombs R . Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008; 198(12):1804-8. PMC: 2665183. DOI: 10.1086/593214. View

Stranska R, Schuurman R, Nienhuis E, Goedegebuure I, Polman M, Weel J . Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol. 2004; 32(1):7-18. DOI: 10.1016/j.jcv.2004.04.002. View

Burioni R, Williamson R, Sanna P, Bloom F, Burton D . Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc Natl Acad Sci U S A. 1994; 91(1):355-9. PMC: 42946. DOI: 10.1073/pnas.91.1.355. View

Freeman E, Weiss H, Glynn J, Cross P, Whitworth J, Hayes R . Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2005; 20(1):73-83. DOI: 10.1097/01.aids.0000198081.09337.a7. View

Co M, Deschamps M, Whitley R, Queen C . Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A. 1991; 88(7):2869-73. PMC: 51341. DOI: 10.1073/pnas.88.7.2869. View

BALZAR M, Winter M, de Boer C, Litvinov S . The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999; 77(10):699-712. DOI: 10.1007/s001099900038. View

Morfin F, Bilger K, Boucher A, Thiebaut A, Najioullah F, Bleyzac N . HSV excretion after bone marrow transplantation: a 4-year survey. J Clin Virol. 2004; 30(4):341-5. DOI: 10.1016/j.jcv.2004.03.002. View

10.

Darville J, Ley B, Roome A, Foot A . Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant. 1998; 22(6):587-9. DOI: 10.1038/sj.bmt.1701392. View

11.

Brooke A, Eveson J, Luker J, Oakhill A . Oral presentation of a novel variant of herpes simplex infection in a group of bone marrow transplant patients: a report of five cases. Br J Dermatol. 1999; 141(2):381-3. DOI: 10.1046/j.1365-2133.1999.03018.x. View

12.

Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I . Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol. 2004; 42(1):242-9. PMC: 321677. DOI: 10.1128/JCM.42.1.242-249.2004. View

13.

Sanna P, De Logu A, Williamson R, Hom Y, Straus S, Bloom F . Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology. 1996; 215(1):101-6. DOI: 10.1006/viro.1996.0011. View

14.

Berrington W, Jerome K, Cook L, Wald A, Corey L, Casper C . Clinical correlates of herpes simplex virus viremia among hospitalized adults. Clin Infect Dis. 2009; 49(9):1295-301. PMC: 2803101. DOI: 10.1086/606053. View

15.

Almagro J, Fransson J . Humanization of antibodies. Front Biosci. 2007; 13:1619-33. DOI: 10.2741/2786. View

16.

Daumer M, Schneider B, Giesen D, Aziz S, Kaiser R, Kupfer B . Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity. Med Microbiol Immunol. 2010; 200(2):85-97. DOI: 10.1007/s00430-010-0174-x. View

17.

Krauss J, Arndt M, Martin A, Liu H, Rybak S . Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Eng. 2003; 16(10):753-9. DOI: 10.1093/protein/gzg096. View

18.

Krawczyk A, Krauss J, Eis-Hubinger A, Daumer M, Schwarzenbacher R, Dittmer U . Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol. 2010; 85(4):1793-803. PMC: 3028897. DOI: 10.1128/JVI.01924-10. View

19.

Blot N, Schneider P, Young P, Janvresse C, Dehesdin D, Tron P . Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant. 2000; 26(8):903-5. DOI: 10.1038/sj.bmt.1702591. View

20.

Zeitlin L, Olmsted S, Moench T, Co M, Martinell B, Paradkar V . A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol. 1998; 16(13):1361-4. DOI: 10.1038/4344. View